The evaluation of continuous data as well as the previously described score [17] showed a significantly lower GLUT-1 level in sarcomas (mean 5.1%, SD 6.2) versus carcinomas (mean 16.5%, SD 17.3) and malignant melanomas (mean 19.0%, SD 20.9, p = 0.001) (Table 2). This evidence concerns the gene SLC2A1 and sarcoma.